KR20200103855A - 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 - Google Patents

만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 Download PDF

Info

Publication number
KR20200103855A
KR20200103855A KR1020207024260A KR20207024260A KR20200103855A KR 20200103855 A KR20200103855 A KR 20200103855A KR 1020207024260 A KR1020207024260 A KR 1020207024260A KR 20207024260 A KR20207024260 A KR 20207024260A KR 20200103855 A KR20200103855 A KR 20200103855A
Authority
KR
South Korea
Prior art keywords
ferric citrate
iron
patient
increase
ferric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207024260A
Other languages
English (en)
Korean (ko)
Inventor
엔리끄 포라도수
론 벤트수르
3세 제임스 에프 올리비에로
Original Assignee
케릭스 바이오파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케릭스 바이오파마슈티컬스 인코포레이티드 filed Critical 케릭스 바이오파마슈티컬스 인코포레이티드
Publication of KR20200103855A publication Critical patent/KR20200103855A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207024260A 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 Ceased KR20200103855A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US61/662,565 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US61/757,229 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
US61/801,050 2013-03-15
US61/800,618 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157001458A Division KR102150135B1 (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Publications (1)

Publication Number Publication Date
KR20200103855A true KR20200103855A (ko) 2020-09-02

Family

ID=49769729

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207024260A Ceased KR20200103855A (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
KR1020157001458A Active KR102150135B1 (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157001458A Active KR102150135B1 (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Country Status (19)

Country Link
US (3) US20130345303A1 (https=)
EP (3) EP3730136B1 (https=)
JP (4) JP2015535209A (https=)
KR (2) KR20200103855A (https=)
CN (2) CN113244209A (https=)
AU (2) AU2013278000A1 (https=)
BR (1) BR112014032049A2 (https=)
CA (1) CA2876982A1 (https=)
DK (1) DK3730136T3 (https=)
EA (1) EA201590062A1 (https=)
ES (2) ES2796254T3 (https=)
FR (1) FR25C1043I1 (https=)
HK (1) HK1214503A1 (https=)
IL (1) IL236356A0 (https=)
MX (1) MX2014015615A (https=)
NO (1) NO2025048I1 (https=)
PL (1) PL3730136T3 (https=)
SG (2) SG11201408521WA (https=)
WO (1) WO2013192565A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
HK1223031A1 (zh) * 2013-11-04 2017-07-21 凯克斯生物制药公司 用於降低慢性肾病患者的心力衰竭的枸橼酸铁
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
US20180071243A1 (en) * 2015-03-04 2018-03-15 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー／エス カルボキシマルトース第二鉄による鉄欠乏症の治療
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922461A4 (en) * 1996-07-19 2002-07-17 Nikken Chemicals Co Ltd MEDICINE AGAINST HYPERPHOSPHATANEMIA
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP1973549B1 (en) * 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型

Also Published As

Publication number Publication date
ES2796254T3 (es) 2020-11-26
EP3730136B1 (en) 2023-12-27
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
HK1214503A1 (zh) 2016-07-29
JP2015535209A (ja) 2015-12-10
EP2863906B1 (en) 2020-03-18
EP4335436A2 (en) 2024-03-13
IL236356A0 (en) 2015-02-26
CN113244209A (zh) 2021-08-13
WO2013192565A2 (en) 2013-12-27
AU2018203205B2 (en) 2020-03-12
MX2014015615A (es) 2015-03-20
US20150079168A1 (en) 2015-03-19
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
SG10201805177PA (en) 2018-07-30
BR112014032049A2 (pt) 2017-07-25
JP2022070945A (ja) 2022-05-13
AU2013278000A1 (en) 2015-01-22
CA2876982A1 (en) 2013-12-27
US20130345303A1 (en) 2013-12-26
PL3730136T3 (pl) 2024-03-25
DK3730136T3 (da) 2024-01-22
KR102150135B1 (ko) 2020-08-31
EP2863906A2 (en) 2015-04-29
NO2025048I1 (no) 2025-11-06
ES2970050T3 (es) 2024-05-24
AU2018203205A1 (en) 2018-05-31
EA201590062A1 (ru) 2016-02-29
EP3730136A1 (en) 2020-10-28
WO2013192565A3 (en) 2015-10-15
JP2018138562A (ja) 2018-09-06
CN104884055A (zh) 2015-09-02
FR25C1043I1 (fr) 2026-01-02
KR20150036131A (ko) 2015-04-07
SG11201408521WA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
KR102150135B1 (ko) 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
Noble et al. Indapamide in the stepped-care treatment of obese hypertensive patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200824

Application number text: 1020157001458

Filing date: 20150120

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201123

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210927

Comment text: Decision to Refuse Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220125

Patent event code: PE09021S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220512

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211224

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210927

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201123

X601 Decision of rejection after re-examination